Clinical investigation of neuroblastoma with partial deletion in the short arm of chromosome 1.
Several loci on the short arm of chromosome 1 (1p) have been reported as the consensus deleted regions for the putative suppressor genes of neuroblastoma by deletion mapping. The significance of deletion in 1p on the clinical features of neuroblastoma remains controversial. To clarify the relationship between the clinical features of neuroblastoma cases and genetic status of 1p, we performed deletion mapping on 1p on samples obtained from 58 cases with neuroblastoma using 12 highly polymorphic microsatellite or minisatellite loci. Loss of heterozygosity of 1p was detected in 19 cases (33%) of primary tumors and in 21 cases (36%) when metastatic and recurrent sites were included. They were classified into two groups according to the 1p deletion pattern: interstitial deletion (group I, n = 11) and terminal deletion (group T, n = 10). The shortest region of overlap in group I ranged between FGR and D1S170 (1p36.1-2). Clinically, all group I cases survived disease free, and none of these cases showed MYCN amplification. However, in group T, eight (80%) cases showed a large terminal deletion from D1S162 (1p32-pter), including the shortest region of overlap of group I, and two (20%) showed a very terminal deletion from D1S160 (1p 36.3). Of the group T cases, only two survived disease free, and seven (70%) showed MYCN amplification. Thus, the candidates for the locations of neuroblastoma suppressor genes on 1p may involve at least two regions, which demonstrate different clinical features.
Ohtsu
K
K
First Department of Surgery and Department of General Medicine, Hiroshima University School of Medicine, 1-2-3 Kasumi, Minami-ku, Hiroshima 734, Japan.
Hiyama
E
E
Ichikawa
T
T
Matsuura
Y
Y
Yokoyama
T
T
D002874:Chromosome Mapping; D002878:Chromosomes, Human, Pair 1; D004273:DNA, Neoplasm / Q000032:analysis / Q000235:genetics; D018572:Disease-Free Survival; D005784:Gene Amplification; D016259:Genes, myc; D005819:Genetic Markers; D006801:Humans; D007223:Infant; D019656:Loss of Heterozygosity; D018895:Microsatellite Repeats; D018598:Minisatellite Repeats; D009367:Neoplasm Staging; D009447:Neuroblastoma / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D011003:Ploidies; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D011379:Prognosis; D016019:Survival Analysis
D004273:DNA, Neoplasm; D005819:Genetic Markers